Glaxon launches new supplement powered by AI-derived PeptiStrong peptide
The product is the first consumer product on the market to incorporate PeptiStrong, an ingredient with reported muscle building, anti-muscle atrophy and anti-inflammation properties. The plant-based ingredient solves the problems of consumers on a calorie restriction, vegan diet or undergoing extremely demanding training sessions, according to Nuritas.
“At a time when consumer demand for naturally-derived ingredients is skyrocketing, we’re excited to be working with such a well-loved brand as Glaxon to bring PeptiStrong to people from all walks of life,” said Dr Nora Khaldi, CEO and Founder of Nuritas, a biotechnology company that combines AI and peptidomics to discover bioactive peptides.
“The benefit of the Nuritas platform is that we can accelerate the discovery of peptides in plant-based foods that can provide tangible health benefits to consumers, allowing our partners to be game-changing in their fields. The speed in which we were able to undergo clinical research and bring the product to market is a testament to our technology and our team of world-class scientists, and we’re excited to continue to innovate with new partners from across nutrition, supplements, beauty, and pet health,” she added.
Joey Savage, Chief Scientific Officer, Zero Day Nutrition, Glaxon’s parent company, added: “People are kind of mind blown. The application for athletes absolutely works. People are starting to use it in several ways, mostly those who are in bodybuilding show prep and want to keep their muscle gains, however others have been using it for bulking or strength and still getting results.”
Anomaly retails for $89.99 and is available via the Glaxon and GNC websites, and in GNC stores across the US.
AI ingredient discovery
Nuritas and its Nuritas MagnifierNπΦ platform offers the potential to unlock plant-based, efficacious solutions to a myriad of health problems, with a reported success rate of up to 1,200 times that of traditional R&D, in 80% less time.
The company has partnered with leading food and pharma companies including Nestle, Mars, Sumitomo Corporation and Pharmavite. Founded in Ireland, Nuritas recently expanded into the US with new North American headquarters in Connecticut. Dr Khaldi relocated to the US to lead the company through its new growth phase.
PeptiStrong is one of Nuritas’ four commercially available ingredients. The other include PeptAIde (modulation of inflammation with respect to exercise), PeptiForce (to increase glucose metabolism), and PeptiYouth (to slow cellular aging).
Pre-clinical data published in Nutrients (Cal et al., 2020, 12(8), 2274) indicated that PeptiStrong may target multiple mechanisms, such as reducing inflammation, boosting muscle synthesis, and downregulating genes related to muscle atrophy. Several human clinical trials are underway or just completed using the ingredient.
“The supplements market in particular offers a unique challenge and opportunity for us because we’ve reached a point where most people in developed countries are now getting enough protein, and yet they still struggle with various muscle problems,” said Dr Khaldi.
“We’ve pushed diet and the current supplements offering as far as they can go. The only way to improve further is through something totally revolutionary and that’s where we come in. We have gone beyond nutrition and created a whole new category of intelligent peptides from nature which can supercharge the efficacy of existing products.”
